Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hydroxyurea therapy.

A S Boyd1, K H Neldner

  • 1Department of Dermatology, Texas Tech University Health Sciences Center, Lubbock 79430.

Journal of the American Academy of Dermatology
|September 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Local delivery of tacrolimus using electrospun poly-ϵ-caprolactone nanofibres suppresses the T-cell response to peripheral nerve allografts.

Journal of neural engineering·2022
Same author

Phaeohyphomycosis caused by Rhytidhysteron rufulum.

Clinical and experimental dermatology·2019
Same author

Localized chronic cutaneous lupus erythematosus masquerading as pigmented lesions: a new clinical subset?

Lupus·2006
Same author

Histiocyte-rich dermatoses in two patients with acute lymphocytic leukaemia treated with cytarabine.

Histopathology·2004
Same author

T-cell clonality in lichenoid purpura: a clinical and molecular evaluation of seven patients.

Histopathology·2003
Same author

The first redox controlled hydrogen bonded three-pole switch.

Chemical communications (Cambridge, England)·2002
Same journal

Hypoactive Sexual Desire Disorder in Menopausal Women: Dermatologic Implications of Antiandrogen and Testosterone Therapy.

Journal of the American Academy of Dermatology·2026
Same journal

Incise parallel, section perpendicular to the dermatoglyphs for diagnosis of acral melanocytic lesions-A comment on Thakker et al.

Journal of the American Academy of Dermatology·2026
Same journal

Response to Xue et al, "Defining super-responders is not the same as predicting rituximab response in pemphigus".

Journal of the American Academy of Dermatology·2026
Same journal

Comment on Nie et al. (2026) 'Suicidality Reports in Acne Patients Treated with Isotretinoin and Concomitant Antidepressants: A Descriptive Analysis of FDA Adverse Event Reporting System Data'.

Journal of the American Academy of Dermatology·2026
Same journal

Defining super-responders is not the same as predicting rituximab response in pemphigus.

Journal of the American Academy of Dermatology·2026
Same journal

Eosinophilic fasciitis induced by checkpoint inhibitors: a retrospective multicenter case-series, comparison with eosinophilic fasciitis unrelated to checkpoint inhibition and literature review.

Journal of the American Academy of Dermatology·2026
See all related articles

Hydroxyurea is an underutilized psoriasis treatment. Despite misconceptions, it offers advantages like ease of dosing and affordability, especially for patients with comorbidities unsuitable for other systemic therapies.

Area of Science:

  • Dermatology
  • Pharmacology

Background:

  • Hydroxyurea's use in psoriasis therapy has declined.
  • Misconceptions exist regarding its efficacy and safety, including concerns about secondary malignancies.
  • Physicians may also question its necessity for a benign condition.

Purpose of the Study:

  • To re-evaluate the role and advantages of hydroxyurea in psoriasis management.
  • To address common misconceptions about hydroxyurea's efficacy and safety profile.
  • To highlight hydroxyurea's suitability for specific patient populations.

Main Methods:

  • Review of existing literature on hydroxyurea for psoriasis.
  • Analysis of hydroxyurea's pharmacokinetic and pharmacodynamic properties.
  • Comparison of hydroxyurea with other systemic psoriasis therapies.

Related Experiment Videos

Main Results:

  • Hydroxyurea is easily dosed, inexpensive, and has few contraindications or subjective side effects.
  • It can be a viable option for patients with hyperlipidemia, mild renal insufficiency, or cardiopulmonary disease.
  • Misconceptions regarding its limited benefit and malignancy risk are challenged.

Conclusions:

  • Hydroxyurea remains a valuable, albeit underutilized, systemic therapy for psoriasis.
  • Its favorable side effect profile and cost-effectiveness warrant consideration.
  • It is particularly beneficial for patients with comorbidities contraindicating other systemic treatments.